NanoViricides, Inc. (NYSE American: NNVC) has announced continued progress in advancing its broad-spectrum antiviral drug candidate NV-387 toward a Phase II clinical trial. The trial will evaluate an oral gummies formulation as a treatment for the current Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo (DRC). The company reported that the proposed clinical trial has been approved by the DRC Pillar Committee, with preparations now underway for ethics and regulatory submissions.
NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical trials, according to NanoViricides. This formulation offers potential advantages in resource-limited outbreak settings where infusion-based therapies can be difficult to deploy. The company highlighted the continued expansion of the outbreak, citing 1,561 confirmed cases and 506 deaths in the DRC as of July 6, while emphasizing that no approved treatment or vaccine currently exists for the Bundibugyo strain.
NanoViricides believes NV-387's broad-spectrum antiviral mechanism could provide activity against multiple ebolavirus strains. The company noted that the same oral gummies formulation has already received approval from DRC regulators for a Phase II trial in Mpox, with product already shipped to the country for that study. Additional details can be found in the full press release at https://ibn.fm/LaNwF.
The company's lead drug candidate is NV-387, a broad-spectrum antiviral drug planned for development as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as Mpox/Smallpox infections and Measles. NanoViricides is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus.
NanoViricides' platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour Pharma, Inc. The company holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of various human viral diseases. As with any drug development efforts, there can be no assurance at this time that any of the company's pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development, or that successful results in the lab will lead to successful clinical trials or a successful pharmaceutical product.
For the latest news and updates relating to NNVC, visit the company's newsroom at https://ibn.fm/NNVC.
